Professor Roberto Caporali (Chair)
University of Milan, Milan, Italy

Roberto Caporali is Professor of Rheumatology at the University of Milan (Milan, Italy) and Head of the Department of Rheumatology and Medical Sciences at the Gaetano Pini Teaching Hospital (Milan, Italy). He is also Director of the post-graduate School of Rheumatology at the University of Milan. He has authored more than 400 papers published in peer-reviewed journals, mainly on RA and other chronic immune-mediated diseases.

Dr James Galloway
King's College Hospital, London, England

James Galloway is a consultant rheumatologist at King's College Hospital, and has specialist interests in the areas of inflammatory arthritis and biologic therapy, and also in sarcoidosis. In addition to research and clinical roles, Dr Galloway is a faculty member of the MBBS undergraduate course in Medicine and has several streams of research aligned to medical education. His research group works on areas including pharmacovigilance, health outcomes and quality improvement in the field of rheumatology.

Professor Bruno Fautrel
Pitié Salpêtrière University Hospital, Pierre et Marie Curie University, Paris, France

Bruno Fautrel is Professor of Rheumatology and Head of the Department of Rheumatology at the Pitié-Salpêtrière University Hospital (Paris, France). He was Principal Investigator of two multicentre trials on the decline of targeted RA therapies and was Coordinating Investigator of a European project on a multiomic approach to autoinflammatory disease diagnosis. He is also Co-director of IMIDIATE, a national network dedicated to clinical investigations in IMIDs.

Dr Lars Erik Kristensen
Parker Institute, Copenhagen, Denmark

Lars Erik Kristensen is Chief Scientific Officer at the Parker Institute (Copenhagen, Denmark). Lars Erik Kristensen is MD from the University of Copenhagen (Copenhagen, Denmark), and specialist in internal medicine, rheumatology from Lund University (Lund, Sweden). His current research activities are focussed on efficacy and tolerability of anti-TNF treatment and other second-generation biologicals in chronic arthritis both in controlled clinical trial settings and observational cohort studies.